New combo therapy aims to boost immune attack on sarcomas before surgery
NCT ID NCT04420975
First seen Mar 24, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This early-phase study tests the safety of combining two immunotherapy drugs—nivolumab and BO-112—given before surgery for soft tissue sarcoma. About 14 adults with removable tumors will receive the drugs to see if they can boost the immune system to fight the cancer more effectively. The main goal is to check for side effects and measure immune changes in the tumor tissue after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.